I am pleased to introduce the third Life Science Competitiveness Indicators. Since the Government launched the last Life Sciences Strategy in 2011 the UK has secured over £7.5bn of inward investment in the sector, leading to the creation of 18,000 new jobs, and today, the UK has one of the strongest and most productive health and life sciences industries in the world.

Now, following the Referendum on leaving the EU, the Government intends to work with all parts of the industry to identify new opportunities presented to maintain and strengthen this position.

This report includes a set of metrics against which UK performance relative to other countries may be compared. For example: in 2015 UK exports grew for the third year in a row, reaching $36.7bn for pharmaceuticals and increased 6% from the previous year.

Despite many positives for the sector, Government recognises that more can be done. In January 2017, we launched the Industrial Strategy Green Paper with a 12 week period of consultation. Through the development of the Life Sciences Industrial Strategy we have listened to the ideas of the sector to ensure the UK remains a top tier global hub and the home of clinical research and medical innovation. Our ambition remains for the UK to be the best place in the world to develop and launch innovative medicines, technologies and diagnostics, for the benefit of patients and boosting growth.

Lord Prior of Brampton
Parliamentary Under Secretary of State for the Department for Business, Energy and Industrial Strategy
Introduction

This Office for Life Sciences (OLS) report brings together a set of competitiveness indicators on the life science environment in the UK and how these compare internationally. This is the third report and it is published alongside the other annual OLS publication – Strength & Opportunity – which provides detailed analysis of the life science sector in the UK.

The 2016 publication seeks continuity with the 2015 publication and so minimal changes have been made to the individual indicators. However, as many of the indicators draws from existing datasets in the public domain, where the underlying data series has changed so the indicators in this publication have changed. Most noticeably, the charts from the 2015 publication which covered Life Science academic citations (charts 12A and 12B in 2015) have been withdrawn from the indicator series as the underlying data has not been refreshed since 2012. Consequently subsequent indicators within the comparative indicator series have been renumbered. In addition, the data series used for science graduates (chart 8) has changed to the percentage of graduates from tertiary education graduating from Natural Sciences, Mathematics and Statistics programmes, both sexes (%) in line with changes made by UNESCO who compile the series.

The web links to public sources along with caveats, as appropriate, are provided for each indicator. The specific data for these charts and tables can be found in the accompanying spreadsheet. In a few instances, it has been necessary for data to be sourced commercially or obtained directly from the organisation holding it. In these cases, the supplier is clearly credited against relevant charts. In cases where the data is from a proprietary source, we have not been able to reproduce the underlying data tables.

The choice of indicators was informed by engagement with life science sector stakeholders. We have selected comparator countries using their advice. However, in some cases this choice has been limited by data availability. We would like to thank all those who have contributed to these indicators, or supplied data for this publication.
Table of contents

Overview: Performance of UK Life Science Sector and Contribution to UK Economy 5
Overview: Competitiveness of UK Life Science Environment 6

**Indicators for UK industry**
- Chart 1A: Number of people employed in manufacture of basic pharmaceutical products and pharmaceutical preparations 8
- Chart 1B: Number of people employed in manufacture of medical technology products 9
- Chart 2: Gross Value Added for pharmaceutical manufacturing 10
- Chart 3A: Exports of pharmaceutical products 11
- Chart 3B: Exports of medical technology products 12
- Chart 4A: Imports of pharmaceutical products 13
- Chart 4B: Imports of medical technology products 14
- Chart 5A: Life sciences foreign direct investment projects 15
- Chart 5B: Life sciences foreign direct investment – capital expenditure 16
- Chart 6A: Share of global life science Initial Public Offerings (IPOs) – 2016 17
- Chart 6B: Initial Public Offerings (IPOs) in life sciences – amount raised in 2016 (where known) 18
- Chart 7A: Private equity investment – total investment 19
- Chart 7B: Number of companies receiving private equity investment 20
- Chart 8: Number of science graduates 21

**Research and Development Indicators**
- Chart 9: Government spend on health research and development 23
- Chart 10: 2015 non-industry spend on research and development 24
- Chart 11: Pharmaceutical industry spend on research and development in the UK 25

**Regulatory Indicator**
- Chart 12: Instances where MHRA is in lead role in EU regulatory procedure 27

**Clinical Research Indicators**
- Chart 13: Share of patients recruited to global studies (all trial phases) 29
- Chart 14: Time from core package received to first patient enrolled in country (all trial phases) 30

**Demand-side Indicators**
- Chart 15: Dashboard of NICE Technology Appraisal publication 32

**Uptake of New Medicines**
- Chart 16A: Uptake of new medicines – NICE approved 34
- Chart 16B: Uptake of new medicines – non-NICE approved 35
Overview:
Performance of UK Life Science Sector and Contribution to UK Economy

Chart 1B: Number of people employed in manufacture of medical technology products


Chart 3A: Exports of pharmaceutical products


Chart 5A: Life sciences foreign direct investment projects

Source: FDI Markets, from The Financial Times Ltd.

Chart 6A: Share of global life science Initial Public Offerings (IPOs) – 2016

Source: S&P Capital IQ http://www.spcapitaliq.com/
Overview: Competitiveness of UK Life Science Environment

Chart 7A: Private equity investment – total investment

<table>
<thead>
<tr>
<th>Year</th>
<th>Ireland</th>
<th>Italy</th>
<th>Switzerland</th>
<th>Spain</th>
<th>Germany</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>0.03</td>
<td>0.6</td>
<td>0.9</td>
<td>1.2</td>
<td>1.5</td>
</tr>
<tr>
<td>2014</td>
<td>0.6</td>
<td>0.9</td>
<td>1.2</td>
<td>1.5</td>
<td>1.8</td>
</tr>
<tr>
<td>2013</td>
<td>0.9</td>
<td>1.2</td>
<td>1.5</td>
<td>1.8</td>
<td>2.1</td>
</tr>
<tr>
<td>2012</td>
<td>1.2</td>
<td>1.5</td>
<td>2.1</td>
<td>2.4</td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>1.5</td>
<td>2.1</td>
<td>2.4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Chart 7B: Number of companies receiving private equity investment

<table>
<thead>
<tr>
<th>Year</th>
<th>Ireland</th>
<th>Italy</th>
<th>Switzerland</th>
<th>Spain</th>
<th>Germany</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>20</td>
<td>40</td>
<td>60</td>
<td>80</td>
<td>100</td>
</tr>
<tr>
<td>2014</td>
<td>40</td>
<td>80</td>
<td>120</td>
<td>140</td>
<td>160</td>
</tr>
<tr>
<td>2013</td>
<td>60</td>
<td>120</td>
<td>160</td>
<td>180</td>
<td>200</td>
</tr>
<tr>
<td>2012</td>
<td>80</td>
<td>160</td>
<td>200</td>
<td>220</td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>100</td>
<td>200</td>
<td>220</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Chart 8: Percentage of graduates from tertiary education graduating from Natural Sciences, Mathematics and Statistics programmes, both sexes (%)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>UK</td>
<td>14</td>
<td>12</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>Ireland</td>
<td>12</td>
<td>10</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Italy</td>
<td>6</td>
<td>5</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Switzerland</td>
<td>8</td>
<td>7</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Spain</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Germany</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>France</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Belgium</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Netherlands</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Sweden</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>USA</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>


Chart 9: Government spend on health research and development

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Belgium</td>
<td>35</td>
<td>30</td>
<td>25</td>
<td>20</td>
<td>15</td>
</tr>
<tr>
<td>Italy</td>
<td>25</td>
<td>20</td>
<td>15</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>Japan</td>
<td>10</td>
<td>8</td>
<td>6</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Spain</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>France</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Germany</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>UK</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

Indicators for UK industry
Chart 1A:
Number of people employed in manufacture of basic pharmaceutical products and pharmaceutical preparations

- UK pharmaceutical employment increased from approximately 37,000 to 39,000 between 2014 to 2015. To note, there is limited data for UK in specific years due to unavailability from Eurostat.
- Germany has continued to have the highest level of employment amongst the selected comparator countries throughout 2010 to 2015.
- The Strength & Opportunity (S&O) annual publication provides details of UK trends in life science sector employment. The S&O report includes supply chain companies, which are an important part of the sector and are excluded here.

Source: Eurostat – Data Explorer, Annual Detailed Enterprise Statistics for Industry

Notes: Not all years are available for each country.
Employment in manufacturing of medical technology in the UK fell from approximately 40,200 to 39,300 between 2014 and 2015.

In 2015, the UK had the fourth highest employment of the selected comparator countries. To note, there is limited data for Turkey, Ireland and France in specific years due to unavailability from Eurostat.

Germany consistently had the highest employment among selected comparator countries throughout 2011 to 2015.

The Strength & Opportunity (S&O) annual publication provides a more complete and up-to-date picture of UK trends in life science sector employment.


Notes: Med Tech chart is compiled from figures for 266 (Manufacture of irradiation, electromedical and electrotherapeutic equipment) + 325 (Manufacture of medical and dental instruments and supplies).
In the UK, the gross value added for pharmaceutical manufacturing was broadly flat between 2014 and 2015 at £9,320m.

In 2016, the UK had the sixth highest gross value added for pharmaceutical manufacturing compared to selected competitor countries.

Germany and Switzerland continue to be two European countries with the largest pharmaceutical manufacturing sectors.

Most recent data for the UK only shows an increase in pharmaceutical GVA of 1.5% on the previous year (ONS).

Source: Comparator countries’ data from Eurostat National Accounts data http://ec.europa.eu/eurostat/web/national-accounts/data/database

Notes: Categories used are “541 Medicinal and pharmaceutical products” and “542 Medicaments including veterinary medicaments”. Data is in current prices.
• Between 2011 and 2015, exports of pharmaceutical products in the UK grew from $35.9 billion to $36.7 billion, a compound annual growth rate of approximately 0.6%.

• In 2015, the UK ranked 6th of comparative countries in value of pharmaceutical product exports.

• Exports from US, UK, Ireland and India all grew between 2014 and 2015.

• Up-to-date UK data, available from ONS, shows a 17% rise in pharmaceutical exports between 2014 and 2015 (ONS).

Source: UNCTAD STAT Data Center

Notes: Categories used from UNCTAD are “541 Medicinal and pharmaceutical products” “542 Medicaments including veterinary medicament”. Data is in current prices.
Between 2011 and 2015, exports of medical technology products in the UK grew from $3.7 billion to $4.1 billion, although most recent years show a decline in exports compared to the previous year.

In 2015, the UK ranked 10th out of the 12 comparative countries in value of medical technology product exports. The UK had a similar level of exports to France and Switzerland.

The US had the highest value of exports in 2015 with an annual growth rate of approximately 2% between 2011 to 2015.

Source: UNCTAD STAT Data Center

Notes: Categories used from UNCTAD STAT are “774 Electro-diagnostic apparatus for medical science etc.” and “872 Instruments and appliances, n.e.s, for medical, etc.” Data is in current prices.
Imports of pharmaceutical products rose in the UK from $26.8 billion in 2011 to $34.5 billion in 2015, a compound annual growth of approximately 6.5%.

- In 2015, the UK had the fourth highest value of imports of pharmaceutical products after the US, Germany and Belgium.
- The US saw a noticeable 17% growth between 2014 to 2015.

Source: UNCTAD STAT Data Center

Notes: Categories used are from UNCTAD “541 Medicinal and pharmaceutical products” “542 Medicaments including veterinary medicament”. Data is in current prices.
• Imports of medical technology products in the UK fell slightly in 2015.

• In 2015, the UK had the eighth highest value of imports among selected comparator countries. The UK had a similar level of imports to France and Belgium.

• Imports of medical technology products have also grown steadily in the US between 2011 and 2015. The US consistently had the highest level among the selected competitor countries.

Source: UNCTAD STAT Data Center

Notes: Categories used from UNCTAD STAT are “774 Electro-diagnostic apparatus for medical science etc.” and “872 Instruments and appliances, n.e.s, for medical, etc.” Data is in current prices.
The number of life science FDI projects in the UK fell from 54 in 2015 to 43 in 2016.

In 2016, the UK ranked second in number of FDI projects among selected comparator countries.

The US have consistently ranked first among selected comparator countries between 2012 and 2016, with 131 projects in total.

Source: fDi Markets, from The Financial Times Ltd.
http://www.fdimarkets.com/explore/?p=sector

Notes: Numbers are for the year that projects were announced. Data is provided to the Office for Life Sciences, by UK Trade & Investment for the purposes of the Competitiveness Indicators publication.
There has been an upward growth in life science foreign direct investment capital expenditure in the UK between 2011 and 2016, although investments can fluctuate markedly from year to year.

In 2016, the UK ranked 6th in capital expenditure among selected comparator countries.

The US life sciences foreign direct investment capital expenditure almost doubled from 2012 to 2016.


Notes: Numbers are for the year that projects were announced. Data is provided to the Office for Life Sciences, by UK Trade & Investment for the purposes of the Competitiveness Indicators publication.
In 2016, the UK had a 4% share of global life science Initial Public Offerings (IPOs).

The UK’s share of global life science IPOs in 2016 was similar to India and Japan.

China (including Hong Kong) had the largest global share of life science IPOs in 2016 with 33%.

The UK’s share of global life science IPOs rose in 2016 from 3% in 2015 [2016 LSCI Report: page 17].

Source: S&P Capital IQ http://www.spcapitaliq.com/

Notes: Numbers refer to the country in which the IPO was launched, not the domicile of the IPO country. ‘Others’ are Belgium, Japan, Vietnam, Bulgaria, Netherlands, Ireland, New Zealand, Denmark, Finland, Norway, Singapore, Switzerland, and Canada.
Chart 6B: Initial Public Offerings (IPOs) in life sciences – amount raised in 2016 (where known)

- Approximately £1,557 million was raised in UK Initial Public Offerings (IPOs) in life sciences in 2016, compared to approximately £107.1 million raised in 2015.
- In 2016, the UK ranked third among selected comparator countries.
- China (including Hong Kong) raised the largest amount of IPOs in life sciences in 2016, with approximately £2,549 million raised.

Source: S&P Capital IQ [http://www.spcapitaliq.com/]

Notes: Numbers refer to the country in which the IPO was launched, not the domicile of the IPO country.
The amount of private equity investment in the UK fell from approximately €0.8 billion to approximately €0.72 billion between 2014 and 2015.

In 2015, the UK ranked third in this investment among selected comparator countries.

Germany experienced significant growth between 2014 and 2015.

Source: Invest Europe

Notes: Data is based on country of portfolio company. Data is in current prices.
The number of companies receiving private equity investment in the UK fell from 118 in 2011 to 71 in 2015.

In 2015, the UK had the third highest number of companies receiving private equity investment among selected comparator countries.

In 2015, Germany had the highest number of companies, despite seeing a decline from 194 in 2011 to 187 in 2015.

Source: Invest Europe

Notes: Data is based on country of portfolio company. Data is in current prices.
The latest figures from the UK continue to show the high proportion of students graduating in sciences and mathematical subjects. In 2014, this was 13% of all graduates.

This is twice the reported proportion of science graduates in the US, although, the larger population pool in the US means it continues to have the largest overall volume of science graduates.

Germany also had a high proportion of science and mathematics graduates (10.5%) in 2014. The UNESCO data series only has one year of data for Germany.

Notes: The data time series, within the "education" theme, produced by UNESCO have changed. Previously, this Life Sciences Competitiveness Indicator set has reproduced the “Science graduates from tertiary education, both sexes (number)” series. As this is now longer available we have switched to including “Percentage of graduates from tertiary education graduating from Natural Sciences, Mathematics and Statistics programmes, both sexes (%).” This has the advantage of standardising for population size, but gives limited insight on the size of the pool of appropriately qualified graduates.
Research and Development Indicators
The most recent data for the UK in the OECD series is for 2014. The UK maintained its position as country with the second highest level of expenditure on health R&D behind the US.

Expenditure in most countries has been flat or falling over the last 5 years. In the UK, expenditure was $3bn in 2014, approximately the same level as in 2013.

Expenditure in the US remained at an order of magnitude of 10 larger than expenditure in comparator countries.


Notes: OECD, has rebased the data used in their series on Government R&D spend from US dollars 2005 to US dollars 2010 at constant prices.
In 2015:
- 44% of UK non-industry spend on R&D was by AMRC member charities
- 24% of UK non-industry spend on R&D was by the Medical Research Council
- 32% of UK non-industry spend on R&D was by the National Institute for Health Research.

In 2014:
- 41% of UK non-industry spend on R&D was by AMRC member charities
- 27% of UK non-industry spend on R&D was by the Medical Research Council
- 32% of UK non-industry spend on R&D was by the National Institute for Health Research.

Expenditure by AMRC member charities increased from £1,286m in 2014 to £1,443m in 2015.


Notes: The data here is reproduced from the Association of Medical Research Charities website.
Between 2003 and 2011, there was steady growth in pharmaceutical industry spend on R&D in the UK followed by a decline from a peak of £4.9bn in 2011 to £3.8bn in 2014.

2015 saw a recovery with expenditure of £4.2bn, representing growth of 8% over the previous year.

Internationally comparable data on pharmaceutical industry spend on R&D is not available, so only UK data is presented here.


Notes: Data is not available for medical technology industry spend.
Regulatory Indicator
Chart 12:
Instances where MHRA is in lead role in EU regulatory procedure

- The MHRA is a leading regulator of choice for scientific advice and centralised procedures.
- In 2016, the MHRA was:
  - Rapporteur/Co-rapporteur in 15.4% of Centralised Procedures;
  - Scientific Advice Co-ordinator in 21% of cases; and
  - Reference Member State in 45% of Decentralised Procedures involving the UK.

Source: Medicines and Healthcare Products Regulatory Agency

Notes: The chart illustrates the proportion of work the UK has undertaken in three key areas of European regulatory activity. As the work of the Medicines and Healthcare Products Regulatory Agency (MHRA) within the areas covered by these indicators is collaborative, no direct comparison with the other 27 Member States is made and the UK’s position in the leading role is shown as a percentage of all work undertaken.

Each new medicine product seeking approval in Europe through the Centralised Procedure has a Rapporteur and a co-Rapporteur appointed by the European Medicines Agency (EMA) to lead the assessment process. The Decentralised Procedure requires the applicant company to select a Reference Member State (RMS) to lead the assessment of the medicine during the procedure.
Clinical Research Indicators
The share of patients recruited to global studies in the UK rose from 1.6% in 2010 to 2.7% in 2014.

Over the last few years, the UK has been working to increase opportunities for patient participation in life sciences industry studies.

This is now making significant impact, with recent data from the National Institute for Health Research (NIHR) showing that the number of participants recruited to commercial contract studies increased from 13,987 in 2010/11 to 34,339 in 2015/16, with the support of the NIHR Clinical Research Network (NIHR).

In addition, the UK has increased its share of European trials, with the UK being represented in 29% of total EU trials in 2016, based on data from the EudraCT database (MHRA and EudraCT).

Source: This material is reproduced under a licence from CMR International.

Notes: You may not copy or re-distribute this material in whole or part without the written consent of CMR International.
In 2014, time from core package received to first patient enrolled in the UK was around 35 days below the peak in 2011.

The UK has put into place several initiatives to reduce start up times for studies with the life sciences industry:

- NHS organisations are nationally benchmarked for study set up times and first participant recruitment.
- Use of standardised model Clinical Trial Agreements and Costing Templates are supporting rapid negotiations around site setup.
- Specific resources have been embedded in the NHS to improve set up times and ensure consistent study delivery.

This is now making significant impact. Data from the National Institute for Health Research (NIHR) shows that the proportion of NHS sites set up within 40 days increased from 24% in 2011/12 to 79% in 2015/16 with the support of the NIHR Clinical Research Network.

Since 2012/13, 74 studies have achieved recruitment of the first global patient in the UK, demonstrating that the UK is globally competitive in the set up and rapid recruitment of participants (NIHR).
Demand-side Indicators
Notes:

MA: Marketing Authorisation
ACD: Appraisal Consultation Document
FAD: Final Appraisal Determination

Dials address forecast and actual timeframes for different stages of the NICE Technology Appraisal process.

Full details of the process, including descriptions of the separate stages can be found on the NICE website

http://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance

Red and Green zones on dials relate to whether milestones have been attained within existing targets for NICE performance.
Uptake of new medicines

- The next two charts show the UK uptake per capita of new medicines compared to a group of comparator countries.

- UK uptake per capita is compared to the average uptake per capita of a group of European and non-European countries: Australia, Austria, Belgium, Canada, Finland, France, Germany, Ireland, Italy, Japan, Netherlands, Spain, Sweden, USA.

- Chart A shows the per capita uptake of 41 new medicines first marketed in the UK between 2011 and 2015 and recommended (or optimised) by NICE for routine funding in the NHS.

- Chart B shows the per capita uptake of 38 medicines first marketed in the UK between 2011 and 2015 and not referred to NICE. Medicines appraised but not recommended by NICE are not included in the analysis.

- The analysis adjusts for population size, but it does not adjust for other important factors which might drive the level of use, such as the number of patients with relevant clinical conditions for each treatments and standard clinical practice at the country level.

- The analysis does not take into account different levels of expenditure on medicines in each country, which is likely to affect uptake.

- Therefore any comparisons and conclusions on the evolution of the uptake of new medicines must be performed with extreme caution.
Chart 16A: Uptake of new medicines – NICE approved

- Chart 16A shows the relative uptake per capita in the UK compared to a selection of other European and non-European countries for a selection of medicines first marketed between 2011 and 2015 and recommended by NICE for routine funding in the NHS.

- Vertical lines refer to the percentages shown on the y-axis and indicate the relative uptake per capita (UK versus other countries) of the individual medicines over a Moving Annual Total (MAT) period of 12 months. The first date of marketing in a country will fall within the first MAT period. The relative uptake figures compare the sales per capita for the UK to the other countries included in the analysis.

- The percentages displayed on the graph represent the median relative uptake per capita in the UK compared with the other countries for all products included in the analysis.

- A value of 100% means UK per capita consumption is identical to the average uptake per capita for the comparison countries during the MAT time window (a percentage higher than 100% indicates that the relative uptake per capita was higher in the UK and a percentage lower than 100% indicates that the uptake was lower in the UK). For example in the 3rd year of launch the median usage of medicines per capita in the UK represented 77.5% of the usage in the comparator countries.

- Medicines launched in 2015 will appear in ‘MAT1’ group, those marketed (corresponding to the first sale made) in 2014 will appear in ‘MAT1’ and ‘MAT2’, etc. The newest medicines will therefore not yet appear in ‘MAT5’.

- The results are specific to the medicines included in the analysis and caution should be exercised when comparing to previous analyses because of the different mix of medicines.

Source: Office of Health Economics analysis based on IMS data.
Chart 16B: Uptake of new medicines – non-NICE reviewed

- Chart 16B shows the relative uptake per capita in the UK compared to a selection of other European and non-European countries for a selection of medicines first marketed between 2011 and 2015 but not referred to NICE. Medicines rejected by NICE are not included in the analysis.

- Vertical lines refer to the percentages shown on the y-axis and indicate the relative uptake per capita (UK versus other countries) of the individual medicines over a Moving Annual Total (MAT) period of 12 months. The first date of marketing in a country will fall within the first MAT period. The relative uptake figures compare the sales per capita for the UK to the other countries included in the analysis.

- The percentages displayed on the graph represent the median relative uptake per capita in the UK compared with the other countries for all products included in the analysis.

- A value of 100% means UK per capita consumption is identical to the average uptake per capita for the comparison countries during the MAT time window relevant to the comparison (a percentage higher than 100% indicates that the relative uptake per capita was higher in the UK and a percentage lower than 100% indicates that the uptake was lower in the UK). For example in the 3rd year of launch the median usage of medicines per capita in the UK represented 67.3% of the usage in the comparator countries.

- Medicines launched in 2015 will appear in ‘MAT1’ group, those marketed (corresponding to the first sale made) in 2014 will appear in ‘MAT1’ and ‘MAT2’, etc. The newest medicines will therefore not yet appear in ‘MAT5’

- The results are specific to the medicines included in the analysis and caution should be exercised when comparing to previous analyses because of the different mix of medicines.

Source: Office of Health Economics analysis based on IMS data.